This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cardiovascular Disease Animal Model Development Service
Introduction
Are you struggling with the complexity of cardiovascular research challenges? BioVenic's integrated cardiovascular disease (CVD) animal model development services offer the solution. Leveraging diverse techniques-genetic modification, surgical induction, dietary challenge, and chemical stimuli-BioVenic constructs and validate high-quality animal models. We provide robust characterization, precise animal experimentation, and bio-sample analysis, helping you to generate reliable efficacy data and simplify your non-GLP preclinical study process.
BioVenic Cardiovascular Disease Animal Model Development Services
Cardiovascular Disease Animal Model Development
BioVenic specializes in establishing a wide array of clinically relevant CVD animal models, ensuring high reproducibility and translational value. BioVenic's expertise spans all major induction principles: genetic (ApoE-/- mice), surgical (Left Coronary Artery Ligation for MI), chemical (ISO-induced Myocardial Damage), and dietary (High-Cholesterol Diets). Crucially, BioVenic team excels in Customized Model Construction. Our advantage is selecting the optimal approach across rodent and large animal species.
Cardiovascular Disease Animal Model Characterization & Verification
To ensure data reliability and confirm model success, rigorous validation is essential. To accurately describe the pathological phenotype, BioVenic uses an extensive verification suite. Common validation methods include:
Physiological & Hemodynamic Assessment: We use invasive methods like Pressure-Volume (P-V) Loop Analysis to make precise assessments of cardiac contractility and relaxation. We also use non-invasive techniques like Echocardiography to find LVEF and measure myocardial wall thickness.
Biochemical Analysis: Involves the evaluation of important circulating biochemistries, including lipid panel analysis (TC, TG, HDL-C, LDL-C), heart damage markers as Troponin I, and inflammatory cytokine profiles.
Pathological & Histological Confirmation: By utilizing techniques such as myocardial fibrosis, myocyte size, and inflammatory cell infiltration through extensive microscopy and macroscopic analysis techniques such as Oil Red O staining to determine plaque area.
Cardiovascular Disease Animal Model Sample Collection
BioVenic provides precise and tailored collection of high-quality biospecimens essential for your molecular and cellular analysis. This includes Terminal Organ Collection (e.g., heart, aorta, lung, kidney), various Blood Fractions (plasma, serum), and specialized processing for downstream assays (e.g., freezing, fixation, or isolation of primary cell populations).
Downstream Experimental Research on CVD Models
BioVenic's integrated platform supports a broad range of subsequent research services using the established cardiovascular disease animal models:
- Efficacy and Dose-Response Studies (Non-GLP).
- Molecular Mechanism of Action (MOA) studies (qPCR, Western Blot, ELISA).
- Imaging and Diagnostic Technology Evaluation (using MRI, CT, and advanced Ultrasound).
Explore BioVenic's investigative modalities:
- Animal Behavioral Analysis
- Animal Histopathology Service
- Preclinical Animal Pharmacodynamics (PD) Study
- Preclinical Animal Pharmacokinetics (PK) Study
- Animal Cell Biology Service
- Animal lmaging Service
BioVenic's animal neurological disease related services also include:
- Genome-edited Animal Model Development
- Chemically-induced Animal Model Development
- Surgically-induced Animal Model Development
Development Workflow for a Cardiovascular Disease Animal Model
Cardiovascular Disease Animal Model Research Areas Overview
Table. 1 Common Cardiovascular Disease Animal Models and Their Research Areas
| Disease Model Type | Modeling Method | Animal Species | Applicable Research Areas |
|---|---|---|---|
| Atherosclerosis (AS) / Hyperlipidemia | Genetic Engineering: ApoE-/- (Apolipoprotein E knockout) mice, Ldlr-/- (Low-Density Lipoprotein Receptor knockout) mice. | Mice (e.g., C57BL/6), Hamsters | Lipid-lowering drug research, AS plaque formation and stabilization mechanisms, Metabolic Syndrome, Vascular inflammation. |
| Diet-Induced: High-fat/ High-cholesterol/ High-fructose diet feeding. | Rats, Mice, Hamsters | ||
| Hypertension | Spontaneous Hypertension: Spontaneously Hypertensive Rats (SHR), Dahl Salt-Sensitive Rats (Dahl/SS). | Rats | Antihypertensive drug screening and efficacy evaluation, research on hypertension complications (e.g., cardiac, cerebral, renal damage). |
| Surgical/ Drug-Induced: Aortic Banding (TAC) (also used for myocardial hypertrophy), Nephrectomy (5/6) (Renal Hypertension), Drug induction. | Rats, Mice | ||
| Myocardial Infarction (MI) / Ischemia-Reperfusion (I/R) Injury | Surgical Ligation: Left Anterior Descending (LAD) coronary artery ligation (Acute MI, Chronic MI, Heart Failure). | Rats, Mice | Anti-myocardial ischemia/infarction drugs, Cardioprotective agents, Cardiac remodeling mechanisms, Cardiogenic shock. |
| Ischemia-Reperfusion: Transient LAD ligation followed by release (I/R injury). | Rats, Mice | ||
| Heart Failure (HF) | Post-MI HF: Coronary artery ligation (large infarct size). | Rats, Mice | Chronic HF drug development, Myocardial remodeling, Cardioprotection. |
| Pressure Overload: Transverse Aortic Constriction (TAC) or Pulmonary Artery Banding. | Rats, Mice | ||
| Drug-Induced: Doxorubicin-induced cardiomyopathy. | Rats, Mice | ||
| Stroke (Cerebral Infarction) | Cerebral Ischemia-Reperfusion: Middle Cerebral Artery Occlusion (MCAO) model (used for transient/permanent cerebral infarction). | Rats, Mice | Neuroprotective drugs, Thrombolytic therapy, Neuroprotection effects, Mechanisms of ischemic brain injury. |
| Thrombosis / Anticoagulation | Arteriovenous (A-V) Shunt Thrombosis Model: Inducing thrombosis via catheter insertion. | Rats, Mice | Screening and evaluation of antithrombotic/thrombolytic/anticoagulant drugs, Platelet aggregation, Coagulation mechanism studies. |
| Carrageenan-Induced Tail Vein Thrombosis: Drug induction. | Mice | ||
| Deep Vein Thrombosis (DVT): Surgical vessel ligation. | Rats | ||
| Anemia | Iron-Deficiency Anemia (IDA): Low-iron diet feeding. | Rats, Mice | Research on iron supplements and erythropoiesis-stimulating agents. |
| Renal Anemia: Nephrectomy (5/6) or Adenine induction. | Rats | Treatment of renal anemia, Effect of kidney disease on hematopoietic function. | |
| Other | Myocardial Hypertrophy: TAC, Drug induction (e.g., Isoproterenol). | Rats, Mice | Study of cardiac hypertrophy mechanisms. |
| Arrhythmia: Drug-induced, Electrical stimulation, Genetic engineering. | Rats, Mice | Antiarrhythmic drugs, Electrophysiology studies. | |
| Hemophilia: F8-KO (Factor VIII knockout) mice. | Mice | Coagulation factor replacement therapy, Hemorrhage control. |
Advantages of BioVenic Cardiovascular Disease Animal Model Development Service
Diverse Existing CVD Model Portfolio
BioVenic combines multiple construction strategies-including genetic, dietary, chemical, and surgical induction-to develop the exact CVD pathology required, selecting the most appropriate animal (from rodents to large animals) to meet your specific research needs.
Customized Project Design
Based on your established research foundation and specific experimental goals, BioVenic integrates the unique characteristics of various CVD animal models with bespoke experimental protocols, ensuring scientific rigor, reliable data, and meaningful conclusions.
Robust Analytical Platform
Beyond model construction, BioVenic possesses a comprehensive platform for both Model Validation (using echocardiography, hemodynamics, etc.) and Sample Analysis (biochemical and histological assays), guaranteeing the quality of both the model and the data derived from it.
Case Study: Specialized Myocardial Fibrosis Modeling & Mechanistic Validation
Our platform offers a highly reproducible animal myocardial fibrosis model in standardized or transgenic mouse lines. To ensure rigorous modeling validation, we provide transthoracic echocardiography to quantify the characteristic decline in contractile function, alongside Masson's Trichrome and Sirius Red staining to characterize interstitial collagen deposition and infarct size. For deep mechanistic insights, we can integrate advanced dual-labeling immunofluorescence (IF) for markers such as CD31 and alpha-SMA, enabling the precise quantification of the Endothelial-to-Mesenchymal Transition. By combining surgical expertise, chemical-inducing method with sophisticated molecular profiling, we provide a robust evaluation framework to help you accelerate the discovery of therapeutic targets and validate the efficacy of anti-fibrotic candidates.
Fig. 1 Characterization of HSPB1 expression in the AMI infarction model1
FAQs
Q: What methods do you use to assess cardiac function?
A: Both invasive and non-invasive techniques are employed. For example, echocardiography assesses cardiac structure and function, and hematoxylin & eosin (HE) staining assesses cardiac tissue structure.
Q: Do you provide services for the development of therapeutic agents for the treatment of chronic diseases?
A: We do offer comprehensive services for preclinical efficacy evaluation of medications used to treat a range of chronic conditions, including atherosclerosis and heart failure. Our services can help with your non-GLP preclinical study.
Q: How do you ensure the models accurately reflects the disease?
A: We use a multi-modal verification strategy. This includes Functional Endpoints (e.g., P-V loop analysis for Heart Failure), Biochemical Markers (e.g., lipid profile for Atherosclerosis), and definitive Histopathology (e.g., quantifying fibrosis/plaque area).
Contact Us
BioVenic's expertise is focused on transforming your cardiovascular research challenges into reliable preclinical data. We offer an unparalleled combination of customizable model construction, validated phenotyping, and robust analytical services, all designed to accelerate your non-GLP studies. Don't let model complexity slow your progress. Contact us today for a comprehensive consultation and a customized quote to advance your most critical research projects!
Reference
- Wang, Jia, et al. "Cardiomyocyte-Derived HSPB1 Regulates TGF-β1 Maturation and Inhibits Endothelial-to-Mesenchymal Transition in Myocardial Fibrosis after Infarction." iScience (2026). https://doi.org/10.1016/j.isci.2026.115028. Distributed under Open Access license CC BY 4.0. Without modification.